Literature DB >> 8560383

Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels.

L E Tisell1, W G Dilley, S A Wells.   

Abstract

BACKGROUND: Patients operated on for medullary thyroid carcinoma (MTC) frequently have persistent elevated plasma calcitonin concentrations after operation, indicating remaining tumor. The plasma calcitonin concentration in a patient with MTC roughly reflects the endogenous tumor burden. The only effective treatment for MTC is surgical. The decision about whether a patient with persistent MTC should have a repeat operation would be influenced by knowledge of the natural course of the disease.
METHODS: Forty patients with persistently elevated peak plasma calcitonin concentrations after thyroidectomy for MTC were monitored for a mean of 6 years. Serial determinations of plasma calcitonin levels were obtained before and after intravenous injection of calcium and pentagastrin.
RESULTS: At the first postoperative test 63% of the patients had undetectable basal calcitonin values, although their stimulated plasma calcitonin concentrations were elevated. The mean annual increase in stimulated plasma calcitonin concentrations was 117%, but plasma calcitonin concentrations were stable in three patients and decreased in one patient. Five patients are known to have experienced distant metastases.
CONCLUSIONS: MTC is a progressive disease in most patients with persistent hypercalcitoninemia after thyroidectomy. Stimulated peak plasma calcitonin levels are more meaningful than basal levels in the serial postoperative evaluation of patients with persistent hypercalcitoninemia after thyroidectomy for MTC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8560383     DOI: 10.1016/s0039-6060(96)80210-8

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  10 in total

1.  Unusual clinical manifestation of pheochromocytoma in a MEN2A patient.

Authors:  M Guerrieri; S Filipponi; G Arnaldi; M Giovagnetti; E Lezoche; F Mantero; A Taccaliti
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

2.  2012 European thyroid association guidelines for metastatic medullary thyroid cancer.

Authors:  M Schlumberger; L Bastholt; H Dralle; B Jarzab; F Pacini; J W A Smit
Journal:  Eur Thyroid J       Date:  2012-03-28

3.  A novel RET inhibitor with potent efficacy against medullary thyroid cancer in vivo.

Authors:  Abbas K Samadi; Ridhwi Mukerji; Anuj Shah; Barbara N Timmermann; Mark S Cohen
Journal:  Surgery       Date:  2010-12       Impact factor: 3.982

Review 4.  Surgical strategy for the treatment of medullary thyroid carcinoma.

Authors:  J B Fleming; J E Lee; M Bouvet; P N Schultz; S I Sherman; R V Sellin; K E Friend; M A Burgess; G J Cote; R F Gagel; D B Evans
Journal:  Ann Surg       Date:  1999-11       Impact factor: 12.969

5.  Medullary thyroid cancer: clinico-pathological profile and outcome in a tertiary care center in North India.

Authors:  Prateek Kumar Mehrotra; Anjali Mishra; Saroj Kanta Mishra; Gaurav Agarwal; Amit Agarwal; Ashok Kumar Verma
Journal:  World J Surg       Date:  2011-06       Impact factor: 3.352

6.  Calcitonin stimulation tests for the early diagnosis and follow-up of patients with C cell disease: a descriptive analysis.

Authors:  I Vainas; A Marthopoulos; A Chrisoulidou; K Raptou; K Tziomalos; K Pazaitou-Panayiotou
Journal:  Hippokratia       Date:  2013-07       Impact factor: 0.471

Review 7.  Medullary thyroid carcinoma: management of lymph node metastases.

Authors:  Frank Jay Quayle; Jeffrey F Moley
Journal:  Curr Treat Options Oncol       Date:  2005-07

Review 8.  The spectrum of thyroid diseases in childhood and its evolution during transition to adulthood: natural history, diagnosis, differential diagnosis and management.

Authors:  C A Koch; N J Sarlis
Journal:  J Endocrinol Invest       Date:  2001-10       Impact factor: 5.467

9.  The Ki67 index a prognostic marker in medullary thyroid carcinoma.

Authors:  L E Tisell; A Oden; A Muth; G Altiparmak; J Mõlne; H Ahlman; O Nilsson
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640

10.  The relevance of somatostatin receptors in thyroid neoplasia.

Authors:  H Ahlman; L E Tisell; B Wängberg; M Fjälling; E Forssell-Aronsson; L Kölby; O Nilsson
Journal:  Yale J Biol Med       Date:  1997 Sep-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.